D-1309-2019 Class I Terminated
FDA drug recall D-1309-2019 was initiated by Novartis Pharmaceuticals Corp. on May 11, 2019 and is designated Class I. Reason for recall: Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour. The recall status is terminated (terminated Nov 28, 2023). Affected quantity: 792 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- May 29, 2019
- Initiation Date
- May 11, 2019
- Termination Date
- Nov 28, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 792 cartons
Product description
Promacta (eltrombopag) 12.5 mg for Oral Suspension, Rx Only Manufactured by: Halo Pharmaceuticals, Inc. Whippany, New Jersey 07981 Distributed by: Novartis Pharmaceuticals Corporation East Hanover, NJ 07936 Product of Ireland, NDC 0078-0972-61.
Reason for recall
Cross Contamination with Other Products: product is being recalled due to possible cross-contamination with peanut flour.
Distribution pattern
Nationwide with in the United States
Code information
Lot #: 8H57901589, Exp. 09/2020; 9H57900189 and 9H57900289, Exp. 12/2020.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1309-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026